This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACU-4429 in Subjects With Geographic Atrophy

This study has been completed.
Otsuka Pharmaceutical Co., Ltd.
Information provided by (Responsible Party):
Acucela Inc. Identifier:
First received: October 26, 2009
Last updated: February 7, 2014
Last verified: February 2014
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of the investigational drug ACU-4429 in subjects with geographic atrophy.

Condition Intervention Phase
Dry Age-related Macular Degeneration Geographic Atrophy Drug: ACU-4429 Drug: Matching placebo Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Multicenter, Randomized, Double-Masked, Placebo-Controlled, Dose Escalation, Multiple-Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACU-4429 in Subjects With Dry Age-Related Macular Degeneration (Geographic Atrophy)

Resource links provided by NLM:

Further study details as provided by Acucela Inc.:

Primary Outcome Measures:
  • Safety as measured by: AEs, clinical laboratory tests, vital signs, physical exams, visual tests, and questionaire [ Time Frame: Through treatment period (up to Day 90) until 1-2 weeks post last dose (Day 97-104) ]

Secondary Outcome Measures:
  • Pharmacokinetics as measured by plasma ACU-4429 drug levels [ Time Frame: Baseline; Treatment Days 2, 7, 14, 30, 60 and 90 ]

Enrollment: 72
Study Start Date: October 2009
Study Completion Date: October 2012
Primary Completion Date: June 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: ACU-4429 tablet Drug: ACU-4429
ACU-4429 tablets (2, 5, 7, or 10 mg) taken orally once daily for 90 days
Placebo Comparator: Matching placebo tablet Drug: Matching placebo
Matching placebo tablets taken orally once daily for 90 days


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Have a clinical diagnosis of geographic atrophy, as defined in the protocol

Exclusion Criteria:

  • Currently receiving or has received a medication prohibited by the protocol
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01002950

United States, Arizona
Retinal Consultants of Arizona
Phoenix, Arizona, United States, 85014
United States, California
Retina-Vitreous Associates Medical Group
Beverly Hills, California, United States, 90211
United States, Florida
Covance Clinical Research Unit, Inc.
Daytona Beach, Florida, United States, 32117
National Ophthalmic Research Institute
Fort Meyers, Florida, United States, 33912
United States, Hawaii
Covance Clinical Research Unit, Inc.
Honolulu, Hawaii, United States, 96813
United States, Michigan
Kresege Eye Institute
Detroit, Michigan, United States, 48201
Associated Retinal Consultants, P.C. / William Beaumont Hospital
Royal Oak, Michigan, United States, 48073
United States, New York
New York Eye and Ear Infirmary
New York, New York, United States, 10003
United States, Ohio
Cleveland Clinic
Cleveland, Ohio, United States, 44195
United States, South Dakota
Black Hills Regional Eye Institute
Rapid City, South Dakota, United States, 57701
United States, Texas
Covance Clinical Research Unit
Austin, Texas, United States, 78752
Covance Clinical Research Unit, Inc.
Dallas, Texas, United States, 75247
Sponsors and Collaborators
Acucela Inc.
Otsuka Pharmaceutical Co., Ltd.
Study Director: John W Chandler, MD Acucela Inc.
  More Information

Responsible Party: Acucela Inc. Identifier: NCT01002950     History of Changes
Other Study ID Numbers: 4429-201
Study First Received: October 26, 2009
Last Updated: February 7, 2014

Additional relevant MeSH terms:
Macular Degeneration
Geographic Atrophy
Retinal Degeneration
Retinal Diseases
Eye Diseases
Pathological Conditions, Anatomical processed this record on September 21, 2017